Skip to main content

Table 2 Health outcomes among HCV patients and controls

From: The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries

 

HCV group

Unmatched controls

Matched controls

 

(n = 286)

(n = 56,880)

(n = 286)

 

Mean

SD

Mean

SD

p-value*

Mean

SD

p-value†

Work impairment

 Absenteeism

7.78%

19.16%

5.44%

19.20%

<.001

5.45%

20.34%

.010

 Presenteeism

26.27%

27.58%

15.83%

22.79%

<.001

14.45%

21.58%

<.001

 Overall work impairment

30.45%

31.42%

19.39%

27.70%

<.001

18.30%

27.47%

<.001

Activity impairment

34.37%

30.60%

24.38%

28.16%

<.001

28.46%

30.57%

.011

Healthcare use

 Annual physician visits

19.80

23.93

10.66

14.64

<.001

13.26

19.21

<.001

 Annual ER visits

0.68

2.11

0.38

1.90

.006

0.39

1.19

.330

 Annual hospitalizations

0.52

1.59

0.26

2.14

<.001

0.27

0.98

.073

Quality of life (SF-12v2)

 MCS

44.17

9.85

46.58

10.59

<.001

46.36

10.79

.012

 PCS

43.61

10.14

48.67

9.75

<.001

46.09

10.33

.004

 Health utility

0.67

0.12

0.73

0.13

<.001

0.71

0.15

.001

  1. Comparisons of work impairment include only the employed subsamples: 138 HCV patients, 32,179 non-HCV, and 134 matched controls.
  2. *Indicates the significance comparing the HCV group with the unmatched control group.
  3. †Indicates the significance comparing the HCV group with the matched control group.
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us